Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02022748 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT02022748 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 27 participants.
The verdict
NCT02022748, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
A phase I, open-label study comparing the pharmacokinetics, pharmacodynamics, safety and tolerability of ticagrelor in hemodialysis patients to healthy subjects with normal renal function.
Interventions
- DRUG ticagrelor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2013-12-29 |
| Est. Completion | 2016-05-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02022748
The ClinicalTrials.gov registry entry for NCT02022748 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ticagrelor is the first listed.
NCT02022748 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02022748 about?
NCT02022748 is a clinical study titled "Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects". A phase I, open-label study comparing the pharmacokinetics, pharmacodynamics, safety and tolerability of ticagrelor in hemodialysis patients to healthy subjects with normal renal function.
What is the current status of trial NCT02022748?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2013-12-29. Estimated completion is 2016-05-09.
What interventions are being tested in trial NCT02022748?
The interventions under investigation include: ticagrelor (DRUG).
Who is sponsoring clinical trial NCT02022748?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.